Development and validation of a dynamic prognostic tool for prostate cancer recurrence using repeated measures of posttreatment PSA: a joint modeling approach.

Prostate-specific antigen (PSA) is a biomarker routinely and repeatedly measured on prostate cancer patients treated by radiation therapy (RT). It was shown recently that its whole pattern over time rather than just its current level was strongly associated with prostate cancer recurrence. To more accurately guide clinical decision making, monitoring of PSA after RT would be aided by dynamic powerful prognostic tools that incorporate the complete posttreatment PSA evolution. In this work, we propose a dynamic prognostic tool derived from a joint latent class model and provide a measure of variability obtained from the parameters asymptotic distribution. To validate this prognostic tool, we consider predictive accuracy measures and provide an empirical estimate of their variability. We also show how to use them in the longitudinal context to compare the dynamic prognostic tool we developed with a proportional hazard model including either baseline covariates or baseline covariates and the expected level of PSA at the time of prediction in a landmark model. Using data from 3 large cohorts of patients treated after the diagnosis of prostate cancer, we show that the dynamic prognostic tool based on the joint model reduces the error of prediction and offers a powerful tool for individual prediction.

[1]  M. Schemper,et al.  Predictive Accuracy and Explained Variation in Cox Regression , 2000, Biometrics.

[2]  C. McCulloch,et al.  Latent Class Models for Joint Analysis of Longitudinal Biomarker and Event Process Data , 2002 .

[3]  Menggang Yu,et al.  Individualized predictions of disease progression following radiation therapy for prostate cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. Heagerty,et al.  Survival Model Predictive Accuracy and ROC Curves , 2005, Biometrics.

[5]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[6]  J. Ware,et al.  Random-effects models for longitudinal data. , 1982, Biometrics.

[7]  H. V. Houwelingen Dynamic Prediction by Landmarking in Event History Analysis , 2007 .

[8]  Robert C. Frazier,et al.  Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy , 1999, Cancer.

[9]  R. Prentice Covariate measurement errors and parameter estimation in a failure time regression model , 1982 .

[10]  Cécile Proust-Lima,et al.  Joint modelling of multivariate longitudinal outcomes and a time-to-event: A nonlinear latent class approach , 2009, Comput. Stat. Data Anal..

[11]  Cécile Proust-Lima,et al.  Determinants of change in prostate-specific antigen over time and its association with recurrence after external beam radiation therapy for prostate cancer in five large cohorts. , 2008, International journal of radiation oncology, biology, physics.

[12]  E Graf,et al.  Assessment and comparison of prognostic classification schemes for survival data. , 1999, Statistics in medicine.

[13]  Paul Schellhammer,et al.  Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. , 2006, International journal of radiation oncology, biology, physics.

[14]  D. Pauler,et al.  Predicting time to prostate cancer recurrence based on joint models for non‐linear longitudinal biomarkers and event time outcomes , 2002, Statistics in medicine.

[15]  A. D'Amico,et al.  Prostate specific antigen doubling time as a surrogate end point for prostate cancer specific mortality following radical prostatectomy or radiation therapy. , 2004, The Journal of urology.

[16]  J. Purdy,et al.  Penile bulb dose and impotence after three-dimensional conformal radiotherapy for prostate cancer on RTOG 9406: findings from a prospective, multi-institutional, phase I/II dose-escalation study. , 2004, International journal of radiation oncology, biology, physics.

[17]  D G Altman,et al.  What do we mean by validating a prognostic model? , 2000, Statistics in medicine.

[18]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.

[19]  M. Wulfsohn,et al.  Modeling the Relationship of Survival to Longitudinal Data Measured with Error. Applications to Survival and CD4 Counts in Patients with AIDS , 1995 .

[20]  Yingye Zheng,et al.  Prospective Accuracy for Longitudinal Markers , 2007, Biometrics.

[21]  Menggang Yu,et al.  JOINT LONGITUDINAL-SURVIVAL-CURE MODELS AND THEIR APPLICATION TO PROSTATE CANCER , 2004 .

[22]  Cécile Proust-Lima,et al.  Determinants of change of prostate-specific antigen over time and its association with recurrence following external beam radiation therapy of prostate cancer in 5 large cohorts , 2010 .

[23]  R Henderson,et al.  Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.

[24]  E Graf,et al.  Quantifying the Predictive Performance of Prognostic Models for Censored Survival Data with Time‐Dependent Covariates , 2008, Biometrics.

[25]  J M Taylor,et al.  Replacing time since human immunodeficiency virus infection by marker values in predicting residual time to acquired immunodeficiency syndrome diagnosis. Multicenter AIDS Cohort Study. , 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[26]  Robin Henderson,et al.  Identification and efficacy of longitudinal markers for survival. , 2002, Biostatistics.

[27]  Yingye Zheng,et al.  Partly Conditional Survival Models for Longitudinal Data , 2005, Biometrics.

[28]  D. Marquardt An Algorithm for Least-Squares Estimation of Nonlinear Parameters , 1963 .

[29]  P. Carroll,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower , 2005 .

[30]  H M Sandler,et al.  Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy. , 1997, International journal of radiation oncology, biology, physics.

[31]  G. Schwarz Estimating the Dimension of a Model , 1978 .

[32]  D. M. Allen,et al.  Determining the number of components in mixtures of linear models , 2001 .